Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIMMER-YOUNG: Ecnoglutide in Overweight or Obese Chinese Adolescents
NCT07836270Phase 3Not yet recruiting
- Sponsor
- Sciwind Biosciences
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ecnoglutide in obesity (4 arms), sponsored by Sciwind Biosciences. Primary endpoint: Percent change in Body Mass Index at 40 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ecnoglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07836270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836270.